Unicycive Therapeutics, Inc. 8-K

What Happened Unicycive Therapeutics, Inc. (UNCY) filed an 8-K on June 22, 2026 reporting the results of its Annual Meeting of Stockholders. A total of 14,964,159 shares of common stock were represented in person or by valid proxy, constituting a quorum. All three director nominees were elected to serve until the 2027 Annual Meeting, and stockholders ratified the appointment of Grassi & Co. CPAs, P.C. as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Key Details

• Total shares represented at the meeting: 14,964,159.
• Director election vote results:
  • Dr. Shalabh Gupta — For: 8,131,958; Withhold: 173,587; Broker Non-Votes: 6,658,614.
  • Dr. Sandeep Laumas — For: 7,696,050; Withhold: 609,525; Broker Non-Votes: 6,658,584.
  • D. Sarawati Kenkare-Mitra — For: 7,510,434; Withhold: 795,108; Broker Non-Votes: 6,658,617.
• Auditor ratification vote results: For 14,667,242; Against 286,958; Abstain 9,928; Broker Non-Vote 31.
• Elected directors will serve until the 2027 Annual Meeting or until their successors are elected and qualified.

Why It Matters These votes finalize Unicycive’s board composition and confirm its independent auditor for fiscal 2026—both governance items investors watch for oversight and financial reporting continuity. The specific vote counts show substantial broker non-votes on the director elections, and near-unanimous support for auditor ratification, which may be relevant when assessing shareholder engagement and governance dynamics.